These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 30181258

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, Daugherty JR, Arbogast PG, García-Rodríguez LA.
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
    [Abstract] [Full Text] [Related]

  • 3. High- vs. low-dose diclofenac and cardiovascular risks: a target trial emulation.
    Schmidt M, Arendt-Nielsen L, Hauge EM, Sørensen HT, Pedersen L.
    Eur Heart J Cardiovasc Pharmacother; 2023 Jul 29; 9(5):453-461. PubMed ID: 36921986
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. NSAIDs and serious cardiovascular disorders: especially cox-2 inhibitors and diclofenac.
    Prescrire Int; 2016 Jan 29; 25(167):14-6. PubMed ID: 26942254
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
    Farkouh ME, Greenberg JD, Jeger RV, Ramanathan K, Verheugt FW, Chesebro JH, Kirshner H, Hochman JS, Lay CL, Ruland S, Mellein B, Matchaba PT, Fuster V, Abramson SB.
    Ann Rheum Dis; 2007 Jun 29; 66(6):764-70. PubMed ID: 17412741
    [Abstract] [Full Text] [Related]

  • 7. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
    Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ, TARGET Study Group.
    Lancet; 2007 Jun 29; 364(9435):665-74. PubMed ID: 15325831
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study.
    Schmidt M, Hallas J, Ernst MT, Pottegård A.
    Eur Heart J Cardiovasc Pharmacother; 2023 Sep 20; 9(6):562-569. PubMed ID: 37385823
    [Abstract] [Full Text] [Related]

  • 11. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec 20; 16(92):223-7. PubMed ID: 18084859
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF, Hsiao FY, Wen YW, Tsai YW.
    Clin Ther; 2006 Nov 20; 28(11):1827-36. PubMed ID: 17213003
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
    van der Linden MW, van der Bij S, Welsing P, Kuipers EJ, Herings RM.
    Ann Rheum Dis; 2009 May 20; 68(5):668-73. PubMed ID: 18495734
    [Abstract] [Full Text] [Related]

  • 16. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
    Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ, Chesebro JH, TARGET Study Group.
    Lancet; 2009 May 20; 364(9435):675-84. PubMed ID: 15325832
    [Abstract] [Full Text] [Related]

  • 17. Differences in cardiovascular safety with non-steroidal anti-inflammatory drug therapy-A nationwide study in patients with osteoarthritis.
    Barcella CA, Lamberts M, McGettigan P, Fosbøl EL, Lindhardsen J, Torp-Pedersen C, Gislason GH, Olsen AS.
    Basic Clin Pharmacol Toxicol; 2019 May 20; 124(5):629-641. PubMed ID: 30484960
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular safety of using non-steroidal anti-inflammatory drugs for gout: a Danish nationwide case-crossover study.
    Bech-Drewes A, Bonnesen K, Hauge EM, Schmidt M.
    Rheumatol Int; 2024 Jun 20; 44(6):1061-1069. PubMed ID: 38581450
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.